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Abstract: There are about fifty SET domain protein methyltransferases (PMTs) in the human genome, that transfer a 
methyl group from S-adenosyl-L-methionine (SAM) to substrate lysines on histone tails or other peptides. A number of 
structures in complex with cofactor, substrate, or inhibitors revealed the mechanisms of substrate recognition, methylation 
state specificity, and chemical inhibition. Based on these structures, we review the structural chemistry of SET domain 
PMTs, and propose general concepts towards the development of selective inhibitors. 
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INTRODUCTION 
  Epigenetics mechanisms rely extensively on histone-
mediated signaling, in which chemical modifications can 
make or break complex biological circuits [1, 2]. Among the 
different histone marks, methylation of specific lysine and 
arginine side-chains can regulate chromatin compaction, 
repress or activate transcription, and control cellular differ-
entiation [3, 4]. The transfer of a methyl group from the co-
factor S-adenosyl-L-methione (SAM) to substrate peptides 
can be catalyzed by two classes of enzymes [5, 6]. Nine ar-
ginine protein methyltransferases (PMTs) are known in hu-
man, whose function, structure, chemistry, and chemical 
inhibition have recently been reviewed [7-9] (Yost et al. this 
issue). Lysine methylation is catalyzed by SET domain 
PMTs, a family of about fifty proteins in human [10], and 
DOT1L, an enzyme that lacks the canonical SET domain, 
but shares the same fold as arginine PMTs [11]. This review 
focuses on the SET domain lysine PMTs. The SET domain 
is a sequence of 130 amino-acids, originally named after the 
Drosophila genes Su(var),  E(z) and Trithorax in which it 
was originally identified. It is defined by a specific fold or-
ganized around a pseudo-knot, and by the presence of two 
signature motifs, ELxF/YDY and NHS/CxxPN, x being any 
amino-acid [12-14].  
  While the SET domain is responsible for catalysis, the 
methyltransferase activity of PMTs also depends on the 
presence of adjacent domains that recruit the substrate, or 
other structural modules, sometimes remote, that act as bind-
ing platforms for interaction partners within large multi-
subunit complexes [10]. For instance, the PMT EZH2 is only 
active within the PRC2 complex when associated with EED 
and SUZ12; recruitment of EED is mediated by a region 
located 500 residues upstream of EZH2’s SET domain [15]. 
Remote structural modules may not be necessary for PMT  
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activity, but sometimes recognize the methylation substrate 
or reaction product. For instance, it was shown that an An-
kyrin repeat distinct from the catalytic domain of GLP could 
recognize mono- or di-methylated lysine 9 of histone 3, the 
very reaction product of GLP’s SET domain [16].  
  As previously observed for histone deacetylases and his-
tone acetyltransferases, it is becoming clear that histones are 
not the only subtrates of some PMTs. For instance, G9a and 
GLP can methylate the tumor suppressor p53 [17]. These 
emerging signaling mechanisms, unrelated to the histone 
code, add to the already large body of evidence associating 
SET domain PMTs to multiple disease areas, and further 
drive the research community towards the development of 
chemical tools to better interrogate their function [3]. 
OVERALL ARCHITECTURE OF THE CATALYTIC 
DOMAIN 
  The catalytic domain is composed of a core SET domain 
that is structurally conserved and includes residues critical 
for catalysis, surrounded with a limited set of regions that 
vary in nature, sequence and shape (Fig. 2). These adjacent 
domains act like a shell around the SET fold, and can be 
divided into two categories. First, the I-SET and post-SET 
domains (respectively inserted within, and immediately C-
terminal to the SET fold) form the binding groove for the 
substrate peptide, and, to a lesser extent, contribute to the 
cofactor binding pocket. A landmark feature of SET domain 
PMTs is that the substrate peptide and cofactor bind distinct 
sites, on different sides of the protein, and meet at the core of 
the structure where catalysis takes place. Available ternary 
complexes of SETD7 and GLP reveal how the side-chain of 
the substrate lysine inserts into a narrow channel at the junc-
tion of the SET, Post-SET, and I-SET domains [14, 18]. In 
this configuration, the lysine is shielded from the solvent, 
which is believed to be required for catalysis [8]. In the 
SETD8 ternary structure, a wide pocket, rather than a chan-
nel, is occupied by the histone lysine and a flanking histidine 
[19, 20]. A catalytically inactive structure of MLL1 features 
a more open peptide binding groove, which leaves the sub-
strate lysine exposed to solvent. Other protein binding part-86    Current Chemical Genomics, 2011, Volume 5  Matthieu Schapira 
ners, part of the MLL complex, are expected to stabilize the 
active conformation, probably closer to that captured by the 
GLP, SETD7 and SETD8 structures [21]. Since both I- and 
Post-SET domains are involved in substrate recognition, it 
comes as no surprise that both are present in all SET domain 
PMTs. The I-SET domain has a fixed topology, and is struc-
turally static, while the post-SET domain adopts variable 
folds and is structurally dynamic, which has implications for 
the mechanism of substrate recognition (vide infra). Avail-
able PRDM structures reveal an extremely short and un-
folded post-SET, which may explain the absence of observed 
biochemical activity for these protein constructs.  
  Other domains surrounding the SET domain include Pre-
SET (N-terminal to SET), N-SET (N-terminal to SET or Pre-
SET), MYND (between SET and I-SET), and CTD (C-
terminal to Post-SET) (Fig. 2). It is believed that some, if not 
all of these variable domains are acting as binding interfaces 
to other proteins or DNA. A general concept would therefore 
be that different combinations of domains with diverse se-
quence, structure, and electrostatics, would dress the core 
SET fold in very distinct ways, and allow selective recruit-
ment of interaction partners, or facilitate specific positioning 
relative to the nucleosome, with functional implications. 
  Recent structures of SMYD proteins illustrate how the 
CTD domain can adopt an open, catalytically competent 
conformation, as observed in SMYD1, or an inactive con-
formation that partially occupies the substrate peptide bind-
ing site (Fig. 3) [22, 23]. It was proposed that binding of 
HSP90, which activates SMYD3, stabilizes the open con-
formation of the protein. Domains adjacent to SET may 
therefore not only act as protein interaction interfaces, but 
also as auto-inhibitory components.  
SUBSTRATE RECOGNITION 
  Display of the molecular surface of PMTs according to 
their electrostatic potential reveals that the substrate-binding 
groove is consistently electronegative, as illustrated Fig. (4) 
for an H3K9, H3K4, and H4K20 PMT (GLP, SETD7 and 
SETD8 respectively). This is in contrast with histone tails, 
which are enriched in lysine and arginine residues, and 
highly electropositive. This observation suggests a general 
mechanism whereby long-range electrostatic attractions can 
bring the PMTs and their peptide substrates together in a 
loose complex, prior to sequence-specific recognition. 
  A close inspection of PMT structures co-crystallized with 
substrate peptides reveals that the substrate lysine is 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Structure coverage of human PMTs mapped on a phylogenetic tree. The phylogeny is based on a multiple sequence alignment 
of the catalytic domain. Structures of SET domain PMTs are shown in red, arginine PMTs in gray and DOT1L (the only non-SET domain 
lysine PMT) in yellow. Ternary complexes with substrate and cofactor are indicated by a star, complexes with the cofactor alone by a full-
circle, and apo-structures by an open-circle. Co-crystallized inhibitors are indicated. Structural Chemistry of Human SET Domain Protein Methyltransferases  Current Chemical Genomics, 2011, Volume 5    87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Architecture of the catalytic domain. The canonical SET domain (green) includes all residues critical to catalysis. The I-SET 
(cyan) and Post-SET (blue) domains are observed in all structures, and form the docking platform for the substrate peptide (magenta). The 
substrate lysine inserts into a narrow channel (top right) and is shielded from solvent. The cofactor (white sticks – top left) and peptide sub-
strate bind at distinct druggable pockets, thereby providing multiple opportunities for chemical inhibition. Diverse combinations of N-SET 
(gray), Pre-SET (orange), MYND (yellow), and CTD (red) domains can dress the core SET domain, and offer distinct interfaces to specific 
interaction partners. The truncated version of the Post-SET domain observed in PRDM structures (bottom left) is probably linked to the ab-
sence of activity of these constructs. (PDB codes are indicated in square brackets). 
anchored in a deep channel, and is the major contributor to 
binding enthalpy. Surprisingly, in all available structures, an 
arginine side-chain located one to four residues upstream or 
downstream the substrate lysine is the next most important 
contributor to interaction, and makes extensive contacts with 
a well-defined cleft of the I-SET domain (Fig. 4) [14, 18, 19, 
21, 24]. Interestingly, the shape, structural environment, and 
position of this cleft relative to the lysine binding channel 
varies from one enzyme to the other, suggesting that it could 
be exploited to design selective inhibitors. This concept was 
validated in the case of G9a and GLP. Indeed, co-crystallized 
selective inhibitors were shown to occupy the arginine bind-
ing site, as discussed below [25, 26]. Another observation 
with possible mechanistic consequences is the fact that his-
tone residues projecting towards the groove are enriched in 
serine and threonine, two other sites of post-translational 
modification. It is tempting to speculate that this trend re-
flects a general structural mechanism where distinct combi-
nations of histone marks would antagonize or possibly en-
hance substrate recognition by specific PMTs. This hypothe-
sis is supported by some experimental observations, but is 
beyond the scope of this study (see for instance [27-29]).  
  As mentioned above, the I-SET domain varies in se-
quence, but is structurally conserved across PMTs. On the 
other hand, the Post-SET domain has variable topologies, 
sometimes organized around a coordinating Zn atom, as is 
observed for instance in the H3K9 PMTs G9a [18], or the 
H3K4 PMT MLL1 [21]. SETD7 was crystallized in its apo 
state, in a binary complex with cofactor, and ternary complex 
with cofactor and substrate peptide [14, 30, 31]. The I-SET 
structure remains unchanged between the three states (with 
the exception of a tryptophan side-chain), while the confor-
mation of the Post-SET domain varies considerably (Fig. 5). 
Interestingly, a sequential mechanism seems to take place: 
the apo-conformation is completely unfolded. Binding of the 
cofactor induces partial folding, where an helix contributing 
to the cofactor binding site adopts its final conformation. 
Finally, proper positioning of the substrate peptide relative to 
the static I-SET induces a final conformational adjustment of 
the Post-SET domain. Based on similar observations, a 88    Current Chemical Genomics, 2011, Volume 5  Matthieu Schapira 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). CTD-mediated auto-inhibition. The CTD domain of SMYD1 and 3 is connected via a hinge to the core structure, and may control 
enzymatic activity by opening or closing the substrate binding site. The left panel is a composite image of the SMYD1 structure with a co-
crystallized H3K4 peptide from a superimposed SETD7 structure (PDB code 1o9s). 
model was proposed for the processivity of substrate methy-
lation where an opening and closing motion of the Post-SET 
domain would allow release into the solvent of the cofactor 
and of a proton from the substrate lysine after a first methy-
lation event. Cofactor exchange and deprotonation of the 
substrate are both necessary before further methylation can 
take place [20]. 
  We propose a general structural mechanism integrating 
electrostatic phenomena, Post-SET dynamics, and histone 
mark cross-talk (Fig. 5). Long range electrostatic attractions 
bring together the electropositive histone tail and a loose 
electronegative binding groove, composed of a pre-formed I-
SET and open Post-SET. SAM binding stabilizes a partially 
folded Post-SET conformation. I-SET acts as a reading plat-
form for the substrate peptide. The PMT may slide along the 
histone tail, held in place by non-specific electrostatics. Once 
a specific combination of histone side-chains comes into 
register with I-SET, the substrate lysine loses a proton to the 
solvent, and the complex clicks into a catalytically compe-
tent conformation where (1) a catalytic tyrsosine located at 
the C-terminus of the SET domain completes formation of 
the lysine channel and projects towards the active site, (2) a 
conserved double-hydrogen bond flanking the substrate ly-
sine is engaged with the I-SET domain, (3) the post-SET 
domain closes onto the bound peptide, shielding the catalytic 
center from solvent. Histone marks deposited by other en-
zymes on flanking serine, threonine or arginine side-chains 
can affect the formation of this catalytically competent state. 
  Structures of the three H3K36 PMTs SETD2, SETMAR, 
and NSD1 (PDB codes 3h6l, 3bo5, 3ooi resp.), and the 
H3K9 tri-methylase SUV39H2 (PDB code 2r3a) are lacking 
a peptide binding groove, which seems to contradict this 
model (Fig. 6, top). In these structures, the I-SET domain 
superimposes well with the I-SET of active structures, such 
as histone-bound GLP, but a side-chain of the Post-SET do-
main projects into what would be the substrate lysine chan-
nel, and flanking Post-SET residues occupy the peptide bind-
ing groove (Fig. 6, bottom). The functional relevance of this 
auto-inhibitory mechanism, originally reported for 
SUV39H2, remains unknown at this time [18]. 
CATALYSIS 
  Catalysis takes place at the SET domain, where the de-
parting methyl of the cofactor lies in close proximity with 
the de-protonated -nitrogen of the substrate lysine, at the 
bottom of the lysine channel (Fig. 7). The nucleophilicity of Structural Chemistry of Human SET Domain Protein Methyltransferases  Current Chemical Genomics, 2011, Volume 5    89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Electrostatics and chemistry of peptide recognition. Top: Electrostatic coloring (red: electronegative, blue: electropositive, gray: 
hydrophobic) reveals that the peptide binding groove is always electronegative, suggesting a long-range, non-specific attraction of electro-
positive histone tails. Bottom: Available ternary structures indicate important but distinct contribution of an arginine flanking the substrate 
lysine to binding enthalpy. Other residues that are also sites of post-translational modifications often occupy the binding groove.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Structural mechanism of peptide recognition. Observations from the apo (yellow, PDB code 1H3I), binary (cyan, PDB code 
1N6C), and ternary (magenta, PDB code 1O9S) structures of SETD7 (top right) can be integrated in a general model for peptide recognition. 
Long-range electrostatics attract non-specifically a loose, negatively charged binding groove (where the I-SET domain is already well struc-
tured, but the Pos-SET not) to positively charged histone tails (bottom left). The I-SET domain acts as a rigid reading platform that scans the 
histone sequence. SAM binding brings the Post-SET domain to a partially folded state, but the binding groove remains sufficiently open to 
allow peptide motion (center). Once a specific sequence is recognized by the I-SET domain, the Post-SET can close in a catalytically compe-
tent conformation (right), the catalytic tyrosine (green) projects towards the site of methyl transfer, and a conserved double hydrogen-bond is 
engaged with I-SET (red crosses). Histone marks deposited by other enzymes, such as kinases or protein arginine methyltransferases 
(PRMTs), on residues flanking the substrate lysine, can antagonize electrostatic attraction (left) and sequence-specific recognition (right).  90    Current Chemical Genomics, 2011, Volume 5  Matthieu Schapira 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Post-SET mediated auto-inhibition. A few SET domain PMT structures are characterized by a lack of peptide binding groove (top 
– the expected location of the groove is indicated by an arrow). In the structures of SETD2, SETMAR and NSD1 (yellow), a side-chain of the 
Post-SET domain is inserted into the substrate lysine channel, which results in a large shift of the Post-SET backbone that occupies the sub-
strate-binding groove. We propose that this represents a mechanism of auto-inhibition. GLP in complex with an H3K9me peptide is shown 
here as a reference structure (Post-SET is blue, I-SET is cyan, substrate lysine is magenta, PDB code 3hna).  
the departing methyl group is enhanced by neighboring main 
chain carbonyl oxygens, and the hydroxyl end of a catalytic 
tyrosine. Another surrounding tyrosine forms a hydrogen 
bond with the substrate lysine, thereby aligning the lone pair 
of the deprotonated -nitrogen with the scissile methyl-sulfur 
bond. A nucleophilic attack follows, which results in methy-
lation of the lysine, and release of SAH [8]. A correlation 
has been observed between the number of residues suscepti-
ble of forming a hydrogen bond with the substrate lysine - 
generally a tyrosine - and the methylation state. Indeed, add-
ing hydrogen bonds restrains the rotational freedom of the 
nitrogen atom, which is necessary to align its lone pair with 
the scissile bond of the sulfonium group. Mutational analy-
ses have confirmed experimentally that a Tyr-Phe switch in 
the active site can effectively control the methylation product 
(Fig. 7) [18, 32-34]. Additionally, the extra bulk created by 
the tyrosine’s hydroxy group, or, as shown in SETD8, by a 
bound water molecule, can sterically prohibit higher methy-
lation states [34]. Interestingly, this switch was recently re-
ported as a frequent somatic mutation in lymphoma, chang-
ing the EZH2 from a multifunctional mono- di- and trimeth-
ylase to an enzyne with increased trimethylase activity, but 
little or no mono- and dimethylase activity [35, 36]. Inhibi-
tors specifically recognizing the mutant enzyme may be of 
interest.  
DRUG DESIGN 
  The cofactor and substrate peptide bind at two distinct 
pockets and meet at the catalytic site (Fig. 2, top). This sug-
gests two avenues for drug design: competitive inhibition of 
cofactor or peptide binding. Potent small molecule inhibitors 
can only be developed if a site is druggable. Selective inhibi-
tion relies on the site’s diversity. Currently the very homolo-
gous enzymes GLP and G9a are the only two lysine PMTs 
that were crystallized in complex with substrate peptide 
competitors: Bix-01294 (IC50 ~1 M), E67 (IC50 ~ 270 
nM), E72 (IC50 ~ 100 nM), UNC0224 (IC50 ~ 15 nM) and 
UNC0638 (IC50 ~ 10 nM) (Fig. 1) [25, 26, 38-40]. We used 
the program SiteMap (Schrodinger, NY) to evaluate the 
druggability of the pockets exploited by these inhibitors (Fig. 
8). A druggability score (Dscore), validated against a large 
training set, is calculated as a function of volume, hydropho-
bicity, and enclosure of the site [41]. A score larger than 0.95 
indicates that the site is druggable; a value below 0.8 reflects 
poor druggability; a Dscore between 0.8 and 0.95 is in the 
gray zone, where no reliable conclusion can be drawn [41]. 
Bix-01294 occupies the open section of the peptide binding 
groove, but does not exploit the lysine channel (Fig. 8). The 
druggability of the corresponding pseudo-site, which artifi-
cially excludes the lysine channel, is unclear. UNC0638, 
another peptide competitor, recapitulates the binding pose of 
Bix-01294, but has an additional aliphatic chain ending with 
a pyrrolidine that extends into the lysine channel (Fig. 8). 
With a Dscore of 1.05, the corresponding site is clearly 
druggable, as confirmed by the high potency of the ligand.  
  We also calculated the druggability of the cofactor bind-
ing site, defined as the pocket occupied by SAM, SAH, or 
the close analogue synefungin. The Dscore varied from 0.92 Structural Chemistry of Human SET Domain Protein Methyltransferases  Current Chemical Genomics, 2011, Volume 5    91 
to 1.1 across all co-crystallized structures of human lysine 
PMTs, with a mean value of 1.0 (Fig. 8). While this site ap-
pears more druggable in some lysine PMTs than others, it is 
predicted to be druggable in all cases. The SETMAR struc-
ture is an exception, with a Dscore of 0.92, due to its particu-
larly high hydrophilicity. This highlights a challenging fea-
ture shared by all enzymes. The cofactor site includes nu-
merous polar groups that cannot be buried by hydrophobic 
ligands without significant desolvation penalty. These must 
be matched by a complex and specific network of hydrogen 
bond donors and acceptors decorating the inhibitor. 
  We have seen that in all available ternary structures, an 
arginine side-chain flanking the substrate lysine is an impor-
tant contributor to binding enthalpy. It is interesting to note 
that the co-crystallized inhibitors all occupy the arginine 
binding site (Fig. 8), a feature that could inspire by analogy 
the design of SETD7 or SETD8 inhibitors (Fig. 4 bottom). 
Interaction hot spots that should be exploited by potent 
chemical inhibitors can be predicted based on receptor-
ligand contacts conserved across all available structures. At 
the peptide binding site, a conserved double hydrogen-bond 
between the backbone of the substrate lysine and a beta-
strand of the I-SET domain seems to be important for the 
interaction (Fig. 9A, top). Interestingly, this interaction is 
partially recapitulated by the pyrrolidine group of the potent 
inhibitor UNC0638 (Fig. 9A, bottom). At the cofactor bind-
ing site, a series of 6 hydrogen bonds engaged with five 
backbone atoms and one conserved asparagine side-chain of 
the SET domain is observed in all available structures (Fig. 
9B, top). These hydrogen-bonds are clustered at two specific 
locations, acting as anchoring point for the cofactor, one at 
the adenine ring, the other at the methionine end. It is likely 
that potent inhibitors will need to mimic this profile of inter-
action. 
  Selective inhibition can only be achieved if the structural 
chemistry of the pocket is sufficiently specific to a given 
enzyme. The peptide binding sites of lysine PMTs have 
evolved to recognize specific sequences. It is therefore rea-
sonable to infer that structural features used to read specific 
sequences can be exploited to design selective inhibitors. 
This is in part confirmed by the selectivity profile of 
UNC0638 an inhibitor that specifically inhibit the H3K9 
PMTs G9a and GLP, but not the H3K4 PMT SETD7, the 
H4K20 PMT SETD8, or even the H3K9 PMT SUV39H2 
[40]). The question of selectivity is not as clear for the cofac-
tor site as it recognizes the same cofactor across all enzymes. 
The chemogenomic profiling of human kinases has demon-
strated that selectivity can be engineered into ATP competi-
tors. A recent study shows that the structural diversity of the 
SAM site in PMTs is comparable to that of the ATP site in 
kinases, suggesting that selective inhibition could be 
achieved at the PMT cofactor site [42]. The selectivity pro-
file of chaetocin, a fungal metabolite that competes with 
SAM with some specificity for H3K9 PMTs, reinforces the 
hypothesis that selective inhibition at the cofactor site is 
chemically tractable [43]. 
  Finally, the peptide and cofactor pockets could be simul-
taneously targeted by bi-substrate competitors, a mode of
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Catalysis and control of methylation specificity. Backbone carbonyl oxygens and a catalytic tyrosine (orange) surrounding the 
departing methyl group of SAM (yellow) favor a nucleophilic attack by the -nitrogen of the substrate lysine (magenta), which must have 
been de-protonated beforehand [8]. A limited number of residues (green, gray, cyan) restrict the alignment of a lone-pair on the accepting 
nitrogen with the scissile sulfur-methyl bond, a geometry necessary for methyl transfer to occur. Mutational analyses reported for G9a [18, 
33], SETD7 [14, 37], SETD8 [34], MLL [21] and somatic mutations reported in EZH2 [35] confirm that these residues control the final 
methylation product: mono-, di- or tri-methyl lysine (Kme, Kme2, or Kme3 respectively). 92    Current Chemical Genomics, 2011, Volume 5  Matthieu Schapira 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Druggability of the peptide and cofactor binding sites. A druggability score was calculated with SiteMap (Schrodinger, NY) for 
the binding sites of the GLP/G9a inhibitors Bix-01294, UNC0638, and the cofactor (top) [41]. The peptide-binding site (center) is druggable, 
and can accommodate highly potent compounds, such as UNC0638. When the lysine channel is ignored, the druggability index drops sharply 
(left). The cofactor site (right) is also predicted to be druggable (blue bar represents the mean value across all available co-crystallized human 
SET domain PMT structures), but with varying druggability index from one enzyme to another (blue error bar), which reflects a variation in 
hydrophilicity and enclosure of the site. Green: pocket used to calculate the druggability score. The molecular surface of the enzyme is 
clipped across the Z-axis for better visualization.  
action that was proposed for existing non-SET domain PMT 
inhibitors [44, 45].  
CONCLUSION 
  We have highlighted general concepts regarding the 
structural mechanism of SET domain PMTs. A variety of 
domains can dress the core SET structure, and act as docking 
platforms for specific binding partners associated with di-
verse cellular events. Sequence and post-translational modi-
fication status of substrate peptides are mainly recognized by 
the I-SET domain, while a limited set of polar groups sur-
rounding the substrate lysine control methylation specificity. 
The peptide and cofactor binding sites are chemically tracta-
ble, and can be targeted by selective small molecule inhibi-
tors, independently or simultaneously. Conserved interaction 
patterns observed in co-crystal structures strongly suggest 
the presence of a discrete number of interaction hotspots that 
can be exploited to achieve potent inhibition.  
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